Drug Utilization Evaluation of Metronidazole at a Tertiary Care Center in Hyderabad, India
Abstract
Drug use evaluation is an on-going, systematic, criteria-based program of medicine evaluations that will help ensure appropriate medicine use. If therapy is determined to be inappropriate, interventions with providers or patients will be necessary to optimize pharmaceutical therapy. In our study we have developed a data collection form based upon WHO guidelines for conducting a DUE study on metronidazole use evaluation. To assess the usage of metronidazole at a tertiary care center Hyderabad a retrospective evaluation of usage patterns was carried out for the period of 6 months corresponding to the dates to 1-1-2018 to 30-6-2018. For conducting the evaluation process we had followed the standard guide lines formulated by WHO. The gender distribution of case sheets were male- 69, female- 80. Indication wise the distribution of case sheets were -43.23% are prophylaxis and surgical prophylaxis, 32.81% are non-indicated and 18, 96% were given for infections. The minimum number of days of treatment was 1 day and the maximum number of days of treatment was 23 days. All patient folders evaluated with regards to cellulitis, gynaecological surgeries, UTI, LRTI etc were found to meet the standard criteria appropriate for metronidazole use with respect to dose, and dose frequency. However, in the case of duration the evaluation was found to be largely inappropriate for all the justified indications. In addition, 34.81% of metronidazole use for unjustified indications was noted. This means that metronidazole has been deviated from standard treatment guidelines hence it facilitates the development of resistant strains to metronidazole and of no use in the near future, and it also affect the patient economically.
Keywords: DUE, Metronidazole, WHO, tertiary care center, Hyderabad.
Downloads
References
2. Available from: www.who.int/.../tbs/11-PG_Drug-Use-Evaluation_final-08.pdf
3. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018657s036lbl.pdf
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.